If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

Framework Agreement with MSC Shipmanagement

27 Jul 2022 07:00

RNS Number : 8355T
Quadrise Fuels International PLC
27 July 2022
 

27 July 2022

 

Quadrise Fuels International plc

("Quadrise," "QFI" or the "Company")

 

Framework Agreement with MSC Shipmanagement Limited

Quadrise (AIM:QFI), the supplier of MSAR® and bioMSAR™ emulsion technology and fuels, providing innovative lower cost and lower carbon alternatives to fuel oil and biofuels, is delighted to announce it has signed a Framework Agreement ("Agreement") with MSC Shipmanagement Limited of Cyprus ("MSC Shipmanagement"), a 100% subsidiary of MSC Mediterranean Shipping Company SA ("MSC").

 

Under the Agreement, proof-of-concept tests and subsequent operational trials will be carried out using both bioMSAR™ and MSAR® fuel on one or more commercial container vessels, as essential precursor steps to the intended commercial supply of these fuels to MSC's global fleet.

 

The proof-of-concept tests for each of bioMSAR™ and MSAR® will be conducted on a vessel now owned by MSC that was previously used for prior successful MSAR® demonstrations on a 69MW 2-stroke engine and commence by no later than 31 December 2022, subject to the ongoing availability of the vessel (the "POC Trials"). Each POC Trial is estimated to require 1,000 metric tons ("MT") of fuel to confirm engine performance on the vessel.

 

Subject to positive results from the POC Trials, the fuels will undergo subsequent operational trials to provide commercial operating experience with a view to obtaining Letters of No Objection ("LONOs") from the engine manufacturer (the "Trials") after proving operational viability of bioMSAR™ and MSAR® at both an interim (midway) and final stage (after circa 4,000 operating hours).

 

It is estimated that approximately 25,000MT of fuel will be required for each of the Trials, with fuel produced by Quadrise and purchased by MSC. In conjunction with the Trials, MSC and Quadrise will jointly continue discussions with other marine engine suppliers to investigate testing bioMSAR™ and MSAR® on their engines.

 

In parallel, subject to the successful progression of the Trial to the Interim LONO stage, Quadrise and MSC intend to negotiate a collaborative commercial agreement (or agreements) to supply bioMSAR™ and/or MSAR® to be used by MSC. The Parties will also investigate opportunities to test the Quadrise Blend-on-Board solution on a suitable MSC vessel.

Commenting on this agreement Jason Miles, CEO of QFI, said:

"This is an important milestone for the Company as we progress our projects and deepen our relationships with leading energy suppliers and users to reduce energy consumption, costs and emissions. Quadrise is delighted to have signed this new agreement with MSC Shipmanagement, the biggest in-house ship management company globally responsible for the largest container ship fleet in the world. We look forward to working with MSC and project stakeholders to demonstrate the commercial viability and environmental benefits of our fuels to the wider seaborne fleet. MSC sets the standard for energy efficiency and biofuel use in the marine sector, and we believe that our bioMSAR™ and MSAR® technology offers an excellent solution to accelerate their decarbonisation and emissions reduction efforts."

Commenting on this agreement Prabhat Jha, Group MD & CEO of MSC Shipmanagement Ltd, said:

"MSC Shipmanagement is delighted to be working with the Quadrise team under this new agreement, as together we have an important enabling role in the marine energy transition towards a net zero carbon future and reducing our own vessel emissions. MSC has one of the youngest fleets among the world's leading shipping lines, and we seek to continually improve energy efficiency by collaborating with suppliers such as Quadrise to promote the wider adoption of low and zero-carbon fuels. We each have an important role to play to accelerate the decarbonisation of the shipping and logistics industry and we look forward to progressing commercial testing of bioMSAR™ and MSAR® technology on our fleet together with Quadrise."

 For further information, please refer to the Company's website at www.quadrisefuels.com or  contact:

 

Quadrise Fuels International Plc

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

+44 (0)20 7031 7321

Nominated Adviser

Cenkos Securities plc

Ben Jeynes

+44 (0)20 7397 8900

Katy Birkin

Broker

Shore Capital Stockbrokers Limited

Toby Gibbs

+44 (0)20 7408 4090

Fiona Conroy

Public & Investor Relations

 

Vigo Consulting

Patrick D'Ancona

Charlie Neish

+44 (0)20 7390 0230

Notes to Editors

 

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology and fuels, providing innovative lower cost and lower carbon alternatives to fuel oil and biofuels in the global power generation, shipping, industrial and refining industries.

 

 

Certain of the information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRSEAFUMEESESW
Date   Source Headline
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension
6th Dec 20214:36 pmRNSPrice Monitoring Extension
1st Dec 20218:00 amEQSEdison Investment Research Limited: Quadrise Fuels International (QFI): Cleaner fuel, cleaner planet
26th Nov 20213:30 pmRNSResult of AGM
26th Nov 20217:00 amRNSAGM Statement
1st Nov 20215:00 pmRNSPosting of Annual Report and Notice of AGM
20th Oct 20215:45 pmRNSMorocco Travel Restrictions
5th Oct 20214:41 pmRNSSecond Price Monitoring Extn
5th Oct 20214:35 pmRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSFinal Results, Directorate Change & Notice of AGM
1st Oct 20217:00 amRNSTotal Voting Rights
24th Sep 20217:00 amRNSNotice of Results and Investor Presentation
23rd Sep 20217:00 amRNSUtah Project Update
20th Sep 20214:36 pmRNSPrice Monitoring Extension
3rd Sep 20212:30 pmRNSIssue of Share Options & Director/PDMR Dealing
2nd Sep 20214:40 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSPublication of bioMSAR Test Results
23rd Aug 20217:00 amRNSGreenfield Commercial Trial Agreement Extension
11th Aug 20217:00 amRNSUpdate on bioMSAR™ Testing
4th Aug 20217:00 amRNSUtah Project Update
30th Jul 20219:30 amRNSBlock Admissions
16th Jul 20214:40 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
16th Jul 20211:15 pmRNSDirectorate Change
28th Jun 20217:00 amRNSUpdate on bioMSAR™ and MSAR® projects
17th May 20214:40 pmRNSSecond Price Monitoring Extn
17th May 20214:35 pmRNSPrice Monitoring Extension
4th May 20219:24 amRNSIssue of Equity
22nd Apr 20214:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20214:36 pmRNSPrice Monitoring Extension
16th Apr 20214:40 pmRNSSecond Price Monitoring Extn
16th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:50 pmRNSUpdate re Greenfield Commercial Trial Agreement
29th Mar 20217:00 amRNSInterim Results
25th Mar 20214:40 pmRNSSecond Price Monitoring Extn
25th Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20217:00 amRNSResults of Open Offer
12th Mar 20217:00 amRNSHolding(s) in Company
10th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSResults of Placing and Open Offer Launch
1st Mar 20214:41 pmRNSProposed Placing and Open Offer
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
23rd Feb 20214:36 pmRNSPrice Monitoring Extension
11th Feb 20214:36 pmRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSFinal Issue of Convertible Securities
4th Feb 20214:41 pmRNSSecond Price Monitoring Extn
4th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.